Skip to main content
main-content

Expert opinion

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.


Concise and thought-provoking commentary, opinion, and analysis from leading oncology experts.

Challenges of an aging and increasingly obese breast cancer survivor population: Are we ready?

Obesity and breast cancer

In an aging population with rising obesity levels, comorbidities and worse overall prognoses for breast cancer patients are a growing concern. Damien Hansra (Cancer Treatment Centers of America, GA, USA) calls for more education and preparation to combat this concerning public health threat.

Discontinuing tyrosine kinase inhibitors in chronic myeloid leukemia

Ehab Atallah

Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Etab Atallah (Medical College of Wisconsin, USA) discusses the current issues surrounding TKI discontinuation in CML.

Pembrolizumab-chemotherapy combination in non-small cell lung cancer

Pembrolizumab-carboplatin-pemetrexed for NSCLC

Two editorial articles provide differing opinions on using pembrolizumab with pemetrexed and platinum chemotherapy for non-small cell lung cancer. In the first article, Stephen Liu argues for embracing this new treatment option, while in the second, Sally Lau and Natasha Leighl argue for a little more caution.

New paradigm: Testing elimination of breast cancer surgery after neoadjuvant systemic therapy

Figure 1

Neoadjuvant chemotherapy can be so effective at shrinking breast tumors in some patients that it has raised the possibility of avoiding surgery altogether. Henry Kuerer (MD Anderson, USA) discusses the exciting recent advances in this area.

Fertility-sparing surgery in high-risk epithelial ovarian cancer: from the patients wishes to the precautionary principle

Fertility sparing surgery

Fertility-sparing surgery is an important option for young women with ovarian cancer but there are questions surrounding its safety in all cases. Philippe Morice and Sébastien Gouy (Institut Gustave Roussy, France) discuss the problems faced in high-risk cases.

Changing landscape of treatment for ALK-positive non-small cell lung cancer

New Content Item

Tremendous advances have been made in the treatment of ALK-positive lung cancers. Advisory Board member Fiona Blackhall summarizes recent developments in the field and discusses current management hurdles, including development of resistance to ALK inhibitors.

Immunotherapy comes of age in blood cancers

New Content Item

Advisory Board member Jasmine Zain discusses the development of various immunotherapy approaches and their potential clinical benefits for patients with blood cancers.

23-04-2018 | Survivorship | Editorial | Article

Challenges of an aging and increasingly obese breast cancer survivor population: Are we ready?

In an aging population with rising obesity levels, comorbidities and worse overall prognoses for breast cancer patients are a growing concern. Damien Hansra (Cancer Treatment Centers of America, GA, USA) calls for more education and preparation to combat this concerning public health threat.

Author:
Damien Hansra MD

02-02-2018 | Chronic myeloid leukemia | Editorial | Article

Discontinuing tyrosine kinase inhibitors in chronic myeloid leukemia

Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Etab Atallah (Medical College of Wisconsin, USA) discusses the current issues surrounding TKI discontinuation in CML.

Author:
Ehab Atallah MD

08-01-2018 | Breast cancer | Editorial | Article

New paradigm: Testing elimination of breast cancer surgery after neoadjuvant systemic therapy

Neoadjuvant chemotherapy can be so effective at shrinking breast tumors in some patients that it has raised the possibility of avoiding surgery altogether. Henry Kuerer (MD Anderson, USA) discusses the exciting recent advances in this area.

Author:
Henry Kuerer MD, PhD, FACS

19-12-2017 | Ovarian cancer | Editorial | Article

Fertility-sparing surgery in high-risk epithelial ovarian cancer: from the patients wishes to the precautionary principle

Fertility-sparing surgery is an important option for young women with ovarian cancer but there are questions surrounding its safety in all cases. Philippe Morice and Sébastien Gouy (Institut Gustave Roussy, France) discuss the problems faced in high-risk cases.

Authors:
Philippe Morice MD, PhD, Sébastien Gouy MD, PhD

26-07-2017 | Non-small cell lung cancer | Editorial | Article

Changing landscape of treatment for ALK-positive non-small cell lung cancer

Tremendous advances have been made in the treatment of ALK-positive lung cancers. Advisory Board member Fiona Blackhall summarizes recent developments in the field and discusses current management hurdles, including development of resistance to ALK inhibitors.

Author:
Fiona Blackhall PhD, FRCP

14-03-2017 | Leukemia | Editorial | Article

FMS-like tyrosine kinase 3 (FLT3)-inhibition in FLT3 mutated acute myeloid leukemia: A promising approach

Advisory Board Member Xavier Thomas discusses the potential of FLT3 inhibitors for the treatment of acute myeloid leukemia.

Author:
Xavier Thomas MD

26-01-2017 | Hematologic cancers | Editorial | Article

Immunotherapy comes of age in blood cancers

Advisory Board member Jasmine Zain discusses the development of various immunotherapy approaches and their potential clinical benefits for patients with blood cancers.

Author:
Jasmine Zain MD
image credits